Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Despite dramatic advances in percutaneous coronary intervention, including coronary stents and potent antiplatelet agents, unfractionated heparin remains the standard procedural anticoagulant. Tradition and habit may have considerable influence over dose selection. A review of the role and dosage of heparin during PCI appears to be overdue

Original publication

DOI

10.1136/heart.88.4.331

Type

Journal article

Journal

Heart

Publication Date

10/2002

Volume

88

Pages

331 - 334

Keywords

Angioplasty, Balloon, Coronary, Anticoagulants, Clopidogrel, Heparin, Heparin, Low-Molecular-Weight, Humans, Platelet Glycoprotein GPIIb-IIIa Complex, Stents, Thrombin, Ticlopidine